NextPoint Therapeutics, Inc.

NextPoint Therapeutics CEO Ivan Cheung will be speaking at the upcoming Piper Sandler Healthcare Conference about the company’s multimodal oncology pipeline that targets B7-H7-positive patients. Check out our press release for the full details: https://bit.ly/3ZktrBI. Not attending the meeting but we piqued your interest and you want to learn more about our novel checkpoint pathway? Reach out and we can set up a time to chat! www.nextpointtx.com

NextPoint Therapeutics CEO Ivan Cheung will be speaking at the upcoming Stifel Healthcare Conference on Tuesday, November 19 at 9:45 am. He will be discussing NextPoint’s pioneering B7-H7 targeted therapies that offer a unique approach beyond traditional PD-L1 pathways. https://bit.ly/4fM6a0T

Uncovering the Potential of B7-H7 Directed T Cell Engagement at #SITC2024. Don't miss our latest preclinical findings demonstrating how this novel approach could overcome the complexities of the tumor microenvironment. Check out our poster and learn more. | https://bit.ly/3Angf5E Not headed to Houston? Reach out and we look forward to connecting! Learn more about us at nextpointtx.com

Congratulations to NextPoint Co-Founder Gordon Freeman!

NextPoint Therapeutics is excited to have CEO Ivan Cheung and CBO Paul Conrad attend the upcoming virtual Leerink Partners' Biopharma Private Company Connect event (Oct 22-23). They will be discussing NextPoint’s pioneering innovative B7-H7 targeted therapies that offer a unique approach beyond traditional PD-L1 pathways. https://bit.ly/3NgCoW5 ? Learn more about us at nextpointtx.com

Barcelona calling! ???? We're gearing up for #ESMO2024 (Sept 13-17). Meet CMO Dr. Leena Gandhi to discuss our precision immuno-oncology approach targeting B7-H7 – a tumor antigen highly expressed in many solid tumors, independent of PD-L1. Learn more about us at nextpointtx.com?

Exciting News! We've unveiled NPX372, a novel T cell engager targeting the B7-H7 axis. NPX372 further expands NextPoint’s multi-modal focus on the emerging B7-H7 axis in cancer therapy. This precision immuno-oncology therapeutic aims to treat solid tumors like colorectal, lung, and renal cancers. ? Preclinical data highlight NPX372’s potent anti-tumor responses and a favorable safety profile at clinically relevant doses with no indication of cytokine release syndrome. Learn more about our diverse portfolio of immunotherapies designed to target various tumor types: nextpointtx.com.

NextPoint’s Chief Scientific Officer Tatiana Novobrantseva will be leading the discussion, “Immunoengineering-Enabling Technology” at the upcoming The Drug Carriers in Medicine and Biology Gordon Research Conference. Not attending the meeting? Be sure to visit nextpointtx.com to learn how the company is launching a new world of precision immuno-oncology and tumor-targeting therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis.

#ICYMI, be sure to check out the poster @NextPoint presented at CIMT in May: “Targeting B7-H7-mediated immunosuppression with NPX267 and NPX887, two fully humanized monoclonal antibodies that target KIR3DL3 and B7-H7, respectively” For more information on how NextPoint’s new class of therapeutics may improve treatment options for cancer patients who do not respond to PD-1/L1 therapy, visit: nextpointtx.com. ?

Chief Medical Officer Leena Gandhi spoke last week at the Next-Gen Immuno-Oncology Conference in Boston about NextPoint Therapeutics, Inc.'s novel class of therapeutics targeting the B7-H7 pathway to improve treatment options for cancer therapy. For more information on NextPoint’s new class of therapeutics to improve treatment options for cancer patients who do not respond to PD-1/L1 therapy, visit: nextpointtx.com. ?